These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38346589)
21. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Sun B; Bird A; Young SP; Kishnani PS; Chen YT; Koeberl DD Am J Hum Genet; 2007 Nov; 81(5):1042-9. PubMed ID: 17924344 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice. Foley JW; Bercury SD; Finn P; Cheng SH; Scheule RK; Ziegler RJ Mol Ther; 2010 Sep; 18(9):1584-91. PubMed ID: 20551907 [TBL] [Abstract][Full Text] [Related]
24. Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease. Han SO; Li S; Everitt JI; Koeberl DD Hum Gene Ther; 2019 Jul; 30(7):855-864. PubMed ID: 30803275 [TBL] [Abstract][Full Text] [Related]
25. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959 [TBL] [Abstract][Full Text] [Related]
26. Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease. Sun B; Li S; Bird A; Koeberl DD Gene Ther; 2010 Dec; 17(12):1500-5. PubMed ID: 20686508 [TBL] [Abstract][Full Text] [Related]
27. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease. Todd AG; McElroy JA; Grange RW; Fuller DD; Walter GA; Byrne BJ; Falk DJ Ann Neurol; 2015 Aug; 78(2):222-34. PubMed ID: 25925726 [TBL] [Abstract][Full Text] [Related]
28. [GAA gene variants and genotype-phenotype correlations in patients with glycogen storage disease type Ⅱ]. Huang YL; Sheng HY; Jia XF; Su XY; Zhao XY; Xie T; Tang CF; Liu SC; Li XZ; Zhang W; Mei HF; Zeng CH; Liu L Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):189-194. PubMed ID: 33657692 [No Abstract] [Full Text] [Related]
29. Salmeterol enhances the cardiac response to gene therapy in Pompe disease. Han SO; Li S; Koeberl DD Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193 [TBL] [Abstract][Full Text] [Related]
30. What's new and what's next for gene therapy in Pompe disease? Roger AL; Sethi R; Huston ML; Scarrow E; Bao-Dai J; Lai E; Biswas DD; El Haddad L; Strickland LM; Kishnani PS; ElMallah MK Expert Opin Biol Ther; 2022 Sep; 22(9):1117-1135. PubMed ID: 35428407 [TBL] [Abstract][Full Text] [Related]
33. Minimum Effective Dose to Achieve Biochemical Correction with Adeno-Associated Virus Vector-Mediated Gene Therapy in Mice with Pompe Disease. Han SO; Gheorghiu D; Li S; Kang HR; Koeberl D Hum Gene Ther; 2022 May; 33(9-10):492-498. PubMed ID: 35102744 [TBL] [Abstract][Full Text] [Related]
34. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy. McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086 [TBL] [Abstract][Full Text] [Related]
35. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263 [TBL] [Abstract][Full Text] [Related]
36. AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice. Meena NK; Randazzo D; Raben N; Puertollano R JCI Insight; 2023 Aug; 8(16):. PubMed ID: 37463048 [TBL] [Abstract][Full Text] [Related]
37. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Douillard-Guilloux G; Raben N; Takikita S; Ferry A; Vignaud A; Guillet-Deniau I; Favier M; Thurberg BL; Roach PJ; Caillaud C; Richard E Hum Mol Genet; 2010 Feb; 19(4):684-96. PubMed ID: 19959526 [TBL] [Abstract][Full Text] [Related]
38. Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease. Schaaf GJ; van Gestel TJM; In 't Groen SLM; de Jong B; Boomaars B; Tarallo A; Cardone M; Parenti G; van der Ploeg AT; Pijnappel WWMP Acta Neuropathol Commun; 2018 Nov; 6(1):119. PubMed ID: 30404653 [TBL] [Abstract][Full Text] [Related]
39. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Zhang P; Sun B; Osada T; Rodriguiz R; Yang XY; Luo X; Kemper AR; Clay TM; Koeberl DD Hum Gene Ther; 2012 May; 23(5):460-72. PubMed ID: 22260439 [TBL] [Abstract][Full Text] [Related]
40. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease. Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]